Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
September 22 2021 - 8:17AM
Business Wire
Company has received more than 570,000 samples
since launching its COVID-19 testing services in 2020 for skilled
nursing homes, businesses, college campuses, health care
facilities, and other venues
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, has implemented its
COVID-19 testing services at more than 30 community college
campuses across California, streamlining the testing and tracking
process for administrators, and allowing students and staff to
easily schedule and complete COVID-19 testing. Since launching
SARS-CoV-2 testing services for customers in June 2020, the company
has received more than 570,000 samples for processing.
Many California community colleges have established COVID-19
vaccine and testing policies for students and staff. To support
these efforts, Biocept is providing PCR-based COVID-19 testing
services that include conveniently located onsite sample collection
at college campuses. Samples are collected by health care providers
and processed at the company’s CLIA-certified, CAP-accredited
laboratory, with results typically available within 48 hours of
receipt.
Biocept also offers a digital platform, created specifically for
its customers, that provides an integrated system for tracking and
managing COVID-19 testing programs. Los Angeles, San Diego and
Riverside community colleges are among the first of a growing
number of campuses that have implemented the digital platform,
allowing students and administrators to record vaccinations,
schedule weekly COVID-19 tests, track results and contact trace
when necessary.
“As colleges return to in-person instruction, simple and
efficient access to COVID-19 testing is essential to the health and
safety of individuals on campus and in the community,” said Michael
Nall, President and CEO of Biocept. “With the emergence of the
Delta variant, we have seen an overall increase in samples, with
more than 50,000 samples received in the last month, and are
prepared for even higher testing volume to accommodate our college
customers. We are proud to provide convenient testing options, ease
administrative burdens and support a safe learning environment for
our college communities.”
Biocept began offering COVID-19 testing to California community
colleges in April 2021, due to its partnership with the Foundation
of California Community Colleges and the CollegeBuys program.
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSideTM cerebrospinal fluid assay, designed to diagnose cancer
that has metastasized to the central nervous system. Biocept also
is leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "could,"
“designed,” “plan,” "expect," or "believe" or the negative of these
words or other variations on these words or comparable terminology.
To the extent that statements in this release are not strictly
historical, including without limitation statements regarding the
ability of Biocept’s testing services to identify and deliver test
results within certain timeframes, continued growth in the number
of campuses implementing Biocept’s integrated digital platform, the
potential for higher volumes of COVID-19 testing and Biocept’s
ability to provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risks and uncertainties,
including the risk that increasing vaccination rates may reduce our
COVID-19 testing volume as well as the adoption of our digital
platform by college campuses, and the risk that our products and
services may not perform as expected. These and other risks are
described in greater detail under the "Risk Factors" heading of our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2021
filed with the Securities and Exchange Commission (SEC) on August
16, 2021. The effects of such risks and uncertainties could cause
actual results to differ materially from the forward-looking
statements contained in this release. We do not plan to update any
such forward-looking statements and expressly disclaim any duty to
update the information contained in this press release except as
required by law. Readers are advised to review our filings with the
SEC, which can be accessed over the Internet at the SEC's website
located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210922005336/en/
Media Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investors Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024